Study Finds Black Adults Are Less Likely to Receive New Alzheimer’s Drugs

secondary stroke prevention

New Alzheimer’s treatments are giving patients and their families some hope, offering a way to slow the disease’s progression. But not everyone has the same opportunity to benefit from these medications.

A new study suggests that Black and Hispanic adults are significantly less likely to receive them than white adults.

Researchers at Michigan Medicine found that Black adults had 86 percent lower odds of receiving anti-amyloid medications than non-Hispanic white adults. Hispanic adults also faced a significant gap, with 79 percent lower odds of receiving treatment.

The findings, published in Neurology, highlight another troubling example of racial disparities in healthcare, this time involving access to newer Alzheimer’s treatments.

Who Gets Access to Alzheimer’s Drugs?

For the study, researchers analyzed health records from more than 1 million adults diagnosed with mild cognitive impairment or dementia. They identified 2,427 patients who received anti-amyloid medications and compared them with patients who did not.

Anti-amyloid medications work by targeting amyloid plaques, which are abnormal protein deposits that build up in the brains of people with Alzheimer’s disease. While they don’t cure the disease or reverse existing damage, they can slow cognitive decline in some people early on.

But accessing these treatments isn’t always easy. Researchers found that race, ethnicity, underlying health conditions, and socioeconomic circumstances all played a role in who received medication. People facing greater social and economic disadvantages were nearly half as likely to receive these newer therapies.

The Problem Starts With Clinical Trials, Too

The treatment gap may actually begin long before a medication reaches the pharmacy. Black Americans are also underrepresented in clinical trials, which can affect how much researchers know about whether new Alzheimer’s treatments work equally well across different populations.

A 2026 study examined 71 Phase 3 Alzheimer’s drug trials conducted in the U.S. between 1997 and 2023. Researchers found that nearly half didn’t report participants’ race or ethnicity. Among the trials that did, white participants made up a median of 91.3 percent of enrollment.

Clinical trials help researchers determine how well treatments work and what side effects patients might experience. When Black adults aren’t adequately represented, researchers have fewer opportunities to evaluate treatment safety and effectiveness across different populations.

The study’s researchers called for more inclusive recruitment efforts, including transportation assistance, language services, financial compensation, and culturally appropriate outreach.

Could a Cancer Drug Also Treat Alzheimer's? Trials Are Testing It

What This Means for Black Families

Alzheimer’s affects more than the person diagnosed. Families often take on significant caregiving responsibilities, making access to treatments that could slow disease progression especially important.

The study’s findings reinforce the importance of early evaluation. Families who notice changes in a loved one’s memory, thinking, or behavior should talk with a healthcare provider rather than dismissing them as a normal part of aging.

Patients diagnosed with early Alzheimer’s can also ask their neurologist whether anti-amyloid medications are appropriate for them. Not everyone qualifies, and these drugs require careful screening and monitoring, but knowing what options are available is an important first step.

What This Means for Clinicians

The findings suggest that inequities in Alzheimer’s treatment access extend beyond diagnosis and into treatment access. Clinicians should ensure that all eligible patients receive timely evaluation, counseling, and referral for anti-amyloid therapies, regardless of their race, ethnicity, or socioeconomic status.

As more Alzheimer’s treatments become publicly available, it’s critical for providers to help address barriers to access and improve representation in clinical trials to achieve equitable care.

AI-Powered Search. Human-Created Content.
What aspect of provider training is most difficult to practice in a traditional educational setting?

Expert Medical Insights, Straight to Your Inbox

Insights That Keep Black Healthcare Leaders at the Forefront

By subscribing, you consent to receive emails from BlackDoctor.pro You may unsubscribe at any time. Privacy Policy & Terms of Service.

Top Articles

Empowering Culturally-Sensitive Healthcare Professionals

BlackDoctor Pro is an online destination created specifically for Black doctors and culturally-sensitive healthcare professionals. Our platform delivers trusted, relevant, and timely medical content, including in-depth articles, the latest treatment updates, healthcare policy, and emerging clinical studies. We are committed to empowering HCPs with the knowledge, resources, and support needed to achieve exceptional health outcomes in black communities.
Copyright © 2026, BlackDoctor, Inc. All rights reserved.
BlackDoctor Pro is an online destination created specifically for Black doctors and other culturally-sensitive healthcare professionals. Our platform delivers trusted, relevant, and timely medical content, including in-depth articles, the latest treatment updates, healthcare policy, and emerging clinical studies.
AI-Powered Search. Human-Created Content.